Sanofi mounts a ‘return to oncology’
Sanofi, which was largely left out of the recent revolution in immunotherapies for cancer, is plotting to catch up quickly, aligning with one of the nation’s largest oncology centers for help.
As STAT’s Elizabeth Cooney reports, the French pharma giant signed a five-year agreement with the University of Texas MD Anderson Cancer Center in hopes of speeding up the development of new medicines. The idea is to use pair Sanofi’s pipeline with MD Anderson’s sizable clinical trial system. The duo’s first joint project will launch this summer.
“The context is Sanofi’s return to oncology,” Dmitri Wiederschain, global head of immuno-oncology research at Sanofi, told STAT. “We are actively rebuilding in both development and early research. And I think we, just like many others, realize that we can’t do it all by ourselves.”
Read more.
As STAT’s Elizabeth Cooney reports, the French pharma giant signed a five-year agreement with the University of Texas MD Anderson Cancer Center in hopes of speeding up the development of new medicines. The idea is to use pair Sanofi’s pipeline with MD Anderson’s sizable clinical trial system. The duo’s first joint project will launch this summer.
“The context is Sanofi’s return to oncology,” Dmitri Wiederschain, global head of immuno-oncology research at Sanofi, told STAT. “We are actively rebuilding in both development and early research. And I think we, just like many others, realize that we can’t do it all by ourselves.”
Read more.
.png)
No hay comentarios:
Publicar un comentario